Health and Healthcare

4 Key Biopharma Movers of the Past Week

Chris Lange

Published: March 20, 2016 10:35 am

Last Updated: January 13, 2020 11:44 am

Over the past week, a few biotech companies made impressive runs. These moves were the result of clinical trial results, U.S. Food and Drug Administration (FDA) decisions and more. The companies 24/7 Wall St. has picked stood out from the rest with positive news guiding them last week. We have included information about each company, as well as recent trading activity and the consensus price target.

GW Pharmaceuticals

On Monday morning, GW Pharmaceuticals PLC (NASDAQ: GWPH) led the bulls out of the gate on news of positive late-stage study results. The company announced the positive results of the first pivotal Phase 3 study of its investigational medicine Epidiolex (cannabidiol) for the treatment of Dravet syndrome.

In this study, Epidiolex achieved the primary endpoint of a significant reduction in convulsive seizures assessed over the entire treatment period compared with the placebo. Epidiolex has both Orphan Drug Designation and Fast Track Designation from the FDA in the treatment of Dravet syndrome, a rare and debilitating type of epilepsy for which there are currently no treatments approved in the United States.

Shares rose nearly 90% over the course of the week, and year to date they are up 5%. The stock traded at $72.72 on Friday’s close. The consensus price target is $148.83, and the 52-week range is $35.83 to $133.98.

24/7 Wall St.
4 Well-Known Health Care Stocks Are Potential Buyout Candidates